Cargando…

Therapeutic potential and molecular mechanisms of salidroside in ischemic diseases

Rhodiola is an ancient wild plant that grows in rock areas in high-altitude mountains with a widespread habitat in Asia, Europe, and America. From empirical belief to research studies, Rhodiola has undergone a long history of discovery, and has been used as traditional medicine in many countries and...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Jingxuan, Luo, Lailiu, Wang, Yicheng, Wu, Shourong, Kasim, Vivi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437267/
https://www.ncbi.nlm.nih.gov/pubmed/36060000
http://dx.doi.org/10.3389/fphar.2022.974775
_version_ 1784781559739449344
author Han, Jingxuan
Luo, Lailiu
Wang, Yicheng
Wu, Shourong
Kasim, Vivi
author_facet Han, Jingxuan
Luo, Lailiu
Wang, Yicheng
Wu, Shourong
Kasim, Vivi
author_sort Han, Jingxuan
collection PubMed
description Rhodiola is an ancient wild plant that grows in rock areas in high-altitude mountains with a widespread habitat in Asia, Europe, and America. From empirical belief to research studies, Rhodiola has undergone a long history of discovery, and has been used as traditional medicine in many countries and regions for treating high-altitude sickness, anoxia, resisting stress or fatigue, and for promoting longevity. Salidroside, a phenylpropanoid glycoside, is the main active component found in all species of Rhodiola. Salidroside could enhance cell survival and angiogenesis while suppressing oxidative stress and inflammation, and thereby has been considered a potential compound for treating ischemia and ischemic injury. In this article, we highlight the recent advances in salidroside in treating ischemic diseases, such as cerebral ischemia, ischemic heart disease, liver ischemia, ischemic acute kidney injury and lower limb ischemia. Furthermore, we also discuss the pharmacological functions and underlying molecular mechanisms. To our knowledge, this review is the first one that covers the protective effects of salidroside on different ischemia-related disease.
format Online
Article
Text
id pubmed-9437267
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94372672022-09-03 Therapeutic potential and molecular mechanisms of salidroside in ischemic diseases Han, Jingxuan Luo, Lailiu Wang, Yicheng Wu, Shourong Kasim, Vivi Front Pharmacol Pharmacology Rhodiola is an ancient wild plant that grows in rock areas in high-altitude mountains with a widespread habitat in Asia, Europe, and America. From empirical belief to research studies, Rhodiola has undergone a long history of discovery, and has been used as traditional medicine in many countries and regions for treating high-altitude sickness, anoxia, resisting stress or fatigue, and for promoting longevity. Salidroside, a phenylpropanoid glycoside, is the main active component found in all species of Rhodiola. Salidroside could enhance cell survival and angiogenesis while suppressing oxidative stress and inflammation, and thereby has been considered a potential compound for treating ischemia and ischemic injury. In this article, we highlight the recent advances in salidroside in treating ischemic diseases, such as cerebral ischemia, ischemic heart disease, liver ischemia, ischemic acute kidney injury and lower limb ischemia. Furthermore, we also discuss the pharmacological functions and underlying molecular mechanisms. To our knowledge, this review is the first one that covers the protective effects of salidroside on different ischemia-related disease. Frontiers Media S.A. 2022-08-19 /pmc/articles/PMC9437267/ /pubmed/36060000 http://dx.doi.org/10.3389/fphar.2022.974775 Text en Copyright © 2022 Han, Luo, Wang, Wu and Kasim. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Han, Jingxuan
Luo, Lailiu
Wang, Yicheng
Wu, Shourong
Kasim, Vivi
Therapeutic potential and molecular mechanisms of salidroside in ischemic diseases
title Therapeutic potential and molecular mechanisms of salidroside in ischemic diseases
title_full Therapeutic potential and molecular mechanisms of salidroside in ischemic diseases
title_fullStr Therapeutic potential and molecular mechanisms of salidroside in ischemic diseases
title_full_unstemmed Therapeutic potential and molecular mechanisms of salidroside in ischemic diseases
title_short Therapeutic potential and molecular mechanisms of salidroside in ischemic diseases
title_sort therapeutic potential and molecular mechanisms of salidroside in ischemic diseases
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437267/
https://www.ncbi.nlm.nih.gov/pubmed/36060000
http://dx.doi.org/10.3389/fphar.2022.974775
work_keys_str_mv AT hanjingxuan therapeuticpotentialandmolecularmechanismsofsalidrosideinischemicdiseases
AT luolailiu therapeuticpotentialandmolecularmechanismsofsalidrosideinischemicdiseases
AT wangyicheng therapeuticpotentialandmolecularmechanismsofsalidrosideinischemicdiseases
AT wushourong therapeuticpotentialandmolecularmechanismsofsalidrosideinischemicdiseases
AT kasimvivi therapeuticpotentialandmolecularmechanismsofsalidrosideinischemicdiseases